Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7168674 | 0.91 | SLC29A1 (0.67) | SLC29A1ALDH1A1LMNAGLAPMP22 | |
| SCHEMBL31307310 | 0.91 | SLC29A1 (0.67) | SLC29A1 | |
| SCHEMBL28821444 | 0.89 | SLC29A1 (0.63) | SLC29A1ALDH1A1LMNAGLAPMP22 | |
| SCHEMBL28894286 | 0.89 | SLC29A1 (0.65) | SLC29A1ALDH1A1LMNAGLAPMP22 | |
| SCHEMBL6382045 | 0.88 | TSHR (0.66) | SLC29A1PMP22SMN1; SMN2ADORA3ADORA1 | |
| SCHEMBL31395324 | 0.86 | SLC29A1 (0.70) | SLC29A1ALDH1A1LMNAGLAPMP22 | |
| SCHEMBL8708994 | 0.86 | SLC29A1 (0.69) | SLC29A1ALDH1A1LMNAGLAPMP22 | |
| SCHEMBL8709002 | 0.86 | SLC29A1 (0.69) | SLC29A1ALDH1A1LMNAGLAPMP22 | |
| SCHEMBL927700 | 0.85 | ADORA1 (0.69) | ADORA3ADORA1 | |
| SCHEMBL6474066 | 0.85 | SLC29A1 (0.68) | SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240358663-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-10-31 | — | — | US | claimed |
| US-20190160029-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-30 | — | — | US | claimed |
| WO-2017192553-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-11-09 | — | — | WO | claimed |
| EP-2204154-B1 | Association of monosaccharides and adenosine and its cosmetic use | ORÉAL L (FR) | 2016-10-12 | — | — | EP | claimed |
| US-20110189255-A1 | DRUG-ELUTING STENTS FOR ADENOSINE RECEPTOR MODULATION | PURDUE RESEARCH FOUNDATION | 2011-08-04 | — | — | US | claimed |
| US-7991601-B2 | Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, crystalline form of same, and screening methods employing same | DUKE UNIVERSITY (US) | 2011-08-02 | — | — | US | claimed |
| US-20100168049-A1 | COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF | L'OREAL (FR) | 2010-07-01 | — | — | US | claimed |
| US-7691969-B2 | Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, crystalline form of same, and screening methods employing same | DUKE UNIVERSITY (US) | 2010-04-06 | — | — | US | claimed |
| US-20080160636-A1 | Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same | DUKE UNIVERSITY (US) | 2008-07-03 | — | — | US | claimed |
| EP-1846578-A2 | METHODS OF IDENTIFYING GENES WHICH MODULATE MYELINATION | Elan Pharmaceuticals Inc. (US) | 2007-10-24 | — | — | EP | claimed |
| US-7235649-B2 | Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same | DUKE UNIVERSITY (US) | 2007-06-26 | — | — | US | claimed |
| EP-1424064-B1 | Use of adenosin or an adenosin analog to smooth out fine lines | OREAL (FR) | 2007-06-06 | — | — | EP | claimed |
| EP-1168912-B1 | ORGAN ARREST, PROTECTION AND PRESERVATION | HIBERNATION THERAPEUTICS LTD (AU) | 2007-05-09 | — | — | EP | claimed |
| WO-2006086761-A2 | METHODS OF IDENTIFYING GENES WHICH MODULATE MYELINATION | ELAN PHARMACEUTICALS, INC. (US) | 2006-08-17 | — | — | WO | claimed |
| US-20060183147-A1 | Methods of identifying genes which modulate myelination | ELAN PHARMACEUTICALS, INC. | 2006-08-17 | — | — | US | claimed |
| EP-1325335-B1 | METHODS FOR DIAGNOSING AND TREATING HUNTINGTON'S DISEASE | UNIV DEGLI STUDI MILANO (IT) | 2006-04-12 | — | — | EP | claimed |
| US-20040146474-A1 | Method for softening lines and relaxing the skin with adenosine and adenosine analogues | L'OREAL (FR) | 2004-07-29 | — | — | US | claimed |
| US-20250387397-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-0544444-A1 | Processes for the preparation f substituted triazolo 1,5-a 1,3,5 triazines | ZENECA LIMITED (GB) | 1993-06-02 | — | — | EP | disclosed |
| EP-0415456-A2 | Xanthine compounds | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080160636-A1 | Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same | HSPA1A, HSPA4L, HSPA4 | SLC29A1 114/4885ALDH1A1 3226/4885LMNA 1412/4885 |
| US-20240358663-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | VASP, MYLK, EDNRB | SLC29A1 2418/4885ALDH1A1 2696/4885LMNA 781/4885 |
| US-20100168049-A1 | COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF | ADORA2A, ADORA1, ADORA3 | SLC29A1 227/4885ALDH1A1 524/4885LMNA 2948/4885 |
| US-20190160029-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | VASP, MYLK, EDNRB | SLC29A1 2418/4885ALDH1A1 2696/4885LMNA 781/4885 |
| US-20250387397-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2A, ADORA2B, ADORA1 | SLC29A1 124/4885ALDH1A1 291/4885LMNA 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.